Clinical trial Recruiting at 1 site Observational Ages 18 to 125

Analysis of lung cancer diagnosis and management in clinical practice

Official title: Landsteiner Lung Cancer Research Platform (LALUCA) A Prospective Analysis of Lung Cancer Diagnosis and Management in Clinical Practice

Run by Karl Landsteiner Institute for Lung Research and Pneumological Oncology · NCT04733430 · Data updated 2026-11-12

This study is trying to see how lung cancer is diagnosed and treated in everyday medical settings to improve care by focusing on genetic testing and treatment options for patients.

More Lung Cancer trials

Quick facts

Study typeObservational
Ages18 Years to 125 Years
SexAll
Enrollment500 (estimated)
SponsorKarl Landsteiner Institute for Lung Research and Pneumological Oncology
Academic / other
Locations1 site (Vienna)
StatusRecruiting
StartedApril 17, 2020
Main results expectedApril 2030
Study endsApril 2030
Registry record updatedMarch 18, 2024
Trial IDNCT04733430 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates for this study are adults aged 18 and older with histologically confirmed lung cancer who can provide informed consent.

Probably not a fit

Patients without a confirmed diagnosis of lung cancer or those unable to provide informed consent may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This project involves a prospective analysis of lung cancer diagnosis and treatment in real-world settings. It aims to establish a clinical platform for collecting data on molecular testing, treatment sequences, and disease progression in lung cancer patients. A key focus is on molecular biomarker testing and next-generation sequencing (NGS) to identify druggable mutations that can improve patient outcomes. The collected data will help assess the current state of lung cancer care and identify areas for improvement.

Why it matters

Potential benefit: If successful, this project could enhance the quality of care and treatment outcomes for lung cancer patients by providing insights into effective diagnostic and therapeutic strategies.

How similar studies have gone: Other studies focusing on molecular testing and NGS in lung cancer have shown promising results, indicating that this approach is supported by previous successful research.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Informed consent
* Histologically confirmed lung cancer
* Age ≥ 18 years
* Able to understand and willing to sign written Informed Consent and to complete patient-reported-outcome assessment instruments

Exclusion Criteria:

\-

Where it's running

  • Karl Landsteiner Institut für Lungenforschung und Pneumologische Onkologie
    Vienna, Austria
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.